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Abstract
Screening for EGFR mutation is a key molecular test for management of lung cancer patients. Outcome of patients with
mutation receiving EGFR tyrosine kinase inhibitor is known to be better across different ethnic populations. However,
frequency of EGFR mutations and the clinical response in most other ethnic populations, including India, remains to be
explored. We conducted a retrospective analysis of Indian lung cancer patients who were managed with oral tyrosine kinase
inhibitors. Majority of the patients in the study had adenocarcinoma and were non-smokers. 39/111 patients tested positive
for EGFR kinase domain mutations determined by Taqman based real time PCR. The overall response to oral TKI therapy was
30%. Patients with an activating mutation of EGFR had a response rate of 74%, while the response rate in patients with wild
type EGFR was 5%, which was a statistically significant difference. Progression free survival of patients with EGFR mutations
was 10 months compared to 2 months for EGFR mutation negative patients. Overall survival was 19 months for EGFR
mutation patients and 13 months for mutation negative patients. This study emphasizes EGFR mutation as an important
predictive marker for response to oral tyrosine kinase inhibitors in the Indian population.
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Introduction
The immense scientific advances made in the past decade have
facilitated the in depth characterization of different disease
subtypes, based on their genetic profiles. This has profound
implications in non small cell lung cancer (NSCLC) which is the
commonest cause of cancer deaths worldwide [1]. The treatment
for NSCLC in the past was based mainly on patient related factors
like the age, performance status and co morbidities. However,
recent molecular advances have changed the treatment landscape
of NSCLC. Key molecular changes like mutation in the epidermal
growth factor receptor (EGFR) are involved in cell proliferation
and cell survival in the neoplasms [2,3].
It has been observed that patients who respond well to an
EGFR inhibitor harbor certain mutations in the EGFR exons 18,
19 or 21. These mutations serve as markers for predicting the
response in patients to oral tyrosine kinase inhibitors targeted to
the EGFR tyrosine kinase. An additional mutation in EGFR exon
20 is known to be responsible for acquired resistance to this
therapy [4]. EFGR tyrosine kinase inhibitors (TKI) have
revolutionized the therapy of NSCLC. In patients whose tumors
harbor the EGFR mutation, the use of an EGFR TKI has led to
increased response rate and prolongation of progression free
survival [5]. EGFRmutations are more likely to occur in patients of
Asian origin, who are female, never-smokers and have adenocar-
cinoma [6]. However, there is very little information regarding
occurrence of EGFR mutations in the Indian population and the
activity of EGFR TKI. There is only one study reported from
India on EGFR mutations in lung cancer, which focuses mainly on
the epidemiology of patients who harbor these mutations [7].
We present the first study from India which correlates the
EGFR mutation status of patients, with their clinical outcome
when treated with oral EGFR TKI. Our study was aimed at
carrying out mutation detection in the DNA extracted from
Formalin Fixed Paraffin Embedded (FFPE) lung biopsies of
NSCLC patients, and to correlate the mutation status with the
response and the the clinical outcome of the patient to EGFR
targeted therapy.
Materials and Methods
The present study was a retrospective analysis of patients with
advanced NSCLC receiving oral EGFR TKI, in whom the EGFR
mutation status was determined. The project was approved by the
Institutional Review Board (IRB) and the Ethics Committee (EC)
of Tata Memorial Hospital (Mumbai, India). This study was
monitored by data monitoring committee of Tata Memorial
Hospital. Since this was a retrospective analysis, the IRB and the
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EC waived the need for an informed consent. Patients were
randomly selected based on the availability of biopsy block from
the database maintained in the Medical Oncology Department at
Tata Memorial Hospital. These patients were started on oral TKI
as part of standard care. DNA extracted from FFPE blocks was
analyzed for EGFR mutation status. The result of the mutation
status was blinded to the treating Physician. Information collected
included demographics, baseline characteristics including smoking
status, histopathology and clinical outcome including toxicity
assessment, response to TKI, progression, therapy at progression
and survival. Response was evaluated according to RECIST v 1.1.
Toxicity was graded according to CTCAE, v4.03. Progression was
defined as clinical deterioration or radiological progression. CT
scans were done every 2 to 4 months or depending on patient’s
symptoms. Data was analyzed using SPSS, v 15. Progression-free
survival was calculated from the date of starting oral TKI to the
date of progression (either symptom deterioration or radiologic
progression), or death from any cause. Overall survival was
calculated from the date of diagnosis to death from any cause.
Median follow-up was calculated for the surviving patients from
date of diagnosis to the date of last follow-up. The study was
conducted in accordance with the declaration of Helsinki and the
International Conference on Harmonization Guidelines for Good
Clinical Practice.
Collection of patient samples
The FFPE blocks of the patients were collected from the
Pathology department of Tata Memorial Hospital. The hematox-
ylin and eosin stained sections from the blocks were mounted on
slides and viewed under the microscope and it was confirmed that
the tumor – region constituted more than 75% of the tissue mass.
Mutation analysis by TaqMan based real time PCR
technique
Taking into account the high frequency of occurrence of specific
mutations in different populations around the world, it was
decided to carry out TaqMan based real time PCR technique for
mutation detection with the help of probes that can anneal
specifically to the mutant or wild type allele. The mutations
studied were in frame deletions in exon 19, L858R point mutation
in exon 21, and the G719C point mutation in exon 18. The assay
was carried out in 384-well reaction plates (Applied Biosystems),
and the reaction was carried out in 5 mL, which contained 2.5 mL
of the Taqman mastermix (Applied Biosystems), primers at a final
concentration of 9 mM and probes at a final concentration of
2 mM; the remaining volume was made up to 5 mL with PCR
grade water. The reaction was carried out at 50uC for 2 minutes
and 95uC for 10 minutes, followed by 40 cycles of 95uC for
15 seconds and 60uC for 1 minute, in the Applied Biosystems
7900 HT machine.
Statistical tests
All statistical analyses were carried out using the SPSS software
version 15.0. The difference between proportions was compared
by Chi square test and the significance value was set at 0.05.
Kaplan Meier curve was plotted for the progression free survival
and the overall survival in months. Log rank test was used to
compare the PFS and OS in different groups.
Results
Characteristics of the study population
Between January 2010 and July 2012, there were 111 patients
who were enrolled in the study from whom a biopsy sample was
available, mutation detection was successfully performed, oral
TKI was used as therapy and full clinical details were available.
The demographics of the patients are shown in the table (Table 1).
TaqMan based real time PCR based screening for EGFR
mutations
Mutation detection results were positive in 39 patients. Among
these, 29 patients were detected to be positive for the in frame
deletion in exon 19. The L858R point mutation in exon 21 was
observed in 9 patients and the G719C point mutation in exon 18
was observed in 1 patient. Most of the above mutations were
heterozygous, except in one patient where the L858R mutation
was found to be a homozygous variant (Table 1).
Clinical Correlation and response to oral tyrosine kinase
inhibitor (TKI)
Among the 39 patients, who were found harboring the
activating mutations, 29 patients had a partial response to oral
TKI therapy, 6 patients had stable disease, while 4 patients had
progressive disease as the best response (Table 2). In the 72
patients in whom no activating mutation was observed, 4 patients
had a partial response, 22 patients had stable disease and 46 had
progressive disease. Thus the response rate to oral TKI for
mutation positive patients was 74%, while the response rate in
mutation negative patients was 5%. The Chi-square test revealed a
significant correlation between the mutation status of the patient
and the response observed, with a p value,0.001.
Survival by EGFR mutation status
The median follow-up was 18 months (range: 16.4 to 19.7
months). The estimated median PFS for the entire cohort of
patients was 4 months (95% CI: 2.5–5.5 months). The estimated
median PFS for the EGFR mutant patients was significantly longer
at 10 months (95% CI: 8–11.9 months) as compared to the
estimated median PFS for EGFR negative patients which was 2
months (95% CI: 1.5–2.5 months), p = 0.000 by log rank test
(Mantel Cox) (Figure 1a). The estimated median OS for all
patients was 13 months (95% CI: 10.7–15.3 months). The
estimated median OS for EGFR positive patients was 21 months
(95% CI: 12.4–25.6 months), while that for EGFR negative
patients was 10 months (95% CI: 7.4–12.6 months), p = 0.001 by
log rank test (Mantel Cox) (Figure 1b).
Toxicity associated with oral tyrosine kinase inhibitor
(TKI)
The main toxicities noted were skin and gastrointestinal, as
detailed in Table 3. Other toxicities noted in 2 patients included
anorexia, fatigue and mucositis. 62 patients experienced no
toxicity.
Discussion
Worldwide, it is now well known that molecular markers,
especially EGFR activating mutations, identify a subset of patients
with NSCLC whose outcome is better with tyrosine kinase EGFR
targeted therapies [5]. However, there is a lack of data from India
regarding EGFR mutation and the response and outcome of these
patients when treated with tyrosine kinase EGFR inhibitors. We
present the first clinical data from India regarding EGFR mutation
in NSCLC patients and the clinical outcome of these patients to
oral TKI therapy.
The majority (81%) of the patients in our study were non-
smokers, a significant proportion (48%) were females and most of
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the patients (96%) had adenocarcinoma. Thus, clearly this was a
clinically enriched population who were chosen for oral TKI
therapy based on clinical parameters and our cohort may not be
truly representative of the actual lung cancer patient pool in India
[8,9].
Table 1. Patient demographics, clinical characteristics and details of EGFR mutation.
Total number of patients 111
Median age (yrs) 55
Gender Males 58
Females 53
Smoking status Smokers 21
Non-smokers 88
EGFR mutation status Mutation positive 39
Mutation negative 72
Type of EGFR mutation Exon 19 In-frame deletions 29
Exon 21 L858R mutation 9
Exon 18 G719C mutation 1
Histopathology Adenocarcinoma 107
Squamous cell carcinoma 4










Line of therapy in which oral TKI was used First line 92
Second line and beyond 19
doi:10.1371/journal.pone.0061561.t001
Table 2. EGFR mutation status of the patients with clinical correlation.
EGFR mutation negative (n =72) EGFR mutation positive (n=39) Statistical test
Smoking Status
Smokers 17 4 Pearson Chi-square test: p:0.075
Non-smokers 53 35
Gender
Males 46 12 Pearson Chi-square test: 0.001
Females 26 27
Histopathology
Adenocarcinoma 69 38 Pearson chi square test: p = 0.67
Squamous cell carcinoma 3 1
Clinical Response
Partial Response 4 29 Pearson Chi-square test:0.000
Stable Disease 22 6
Progressive Disease 46 4
PFS (months) 2 10 Long rank test (Mantel-Cox): 0.000
OS (months) 9 19 Long rank test (Mantel-Cox): 0.001
doi:10.1371/journal.pone.0061561.t002
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In our study, 39 out of 111 patients, i.e. 35% of the patients
were found to harbor an EGFR mutation. The previous study from
India found that the mutation rate was 51.8% [7]. It is likely that
both our study and the prior Indian report overestimated the
incidence of EGFR mutation, because of a small sample size and
clinically selected patients. Worldwide, the incidence of EGFR
mutations has been well characterized and has been reported to
occur at the rate of 10–15% in North Americans and Europeans,
19% in African-Americans and about 30% in East Asians [10–13].
We found that 35 of the 39 patients with EGFR mutations (90%)
were non-smokers, while 53 of the 70 patients who were EGFR
mutation negative (76%) had a smoking history. Regarding a
gender predilection, 27 of the 39 patients with EGFR mutations
(69%) were female while 46 of 72 patients with EGFR-negative
tumors (64%) were male. Given that the overwhelming majority of
patients in our study had adenocarcinoma (96%) and all patients
were from India, it is impossible to comment on the correlation of
pathology or ethnicity to EGFR mutation status.
Regarding the type of EGFR mutations detected, 74% of the
patients were noted to have in frame deletion in exon 19, 23% had
the L858R point mutation in exon 21 and only 2.5% patients had
the G719C point mutation in exon 18. In the reported literature,
approximately 45 to 54% of EGFR mutations are in-frame
deletions in exon 19, while approximately 40% of EGFRmutations
are missense mutations in L858R in exon 21 and between 4 to 9%
of the mutations were reported in exon 20 [5].
The toxicity noted in our patients was similar to that described
in the literature, although less toxicities were noted than what have
been previously described. We did not have any case of interstitial
lung disease as a result of oral TKI therapy. In the IPASS study,
66% of patients developed rash and 47% of the patients
experienced gastrointestinal toxicity. The retrospective nature of
our analysis may be one of the reasons why toxicities were noted to
a lesser extent; however Indian patients may experience less
toxicities as a result of EGFR targeted therapies due to various
factors like ethnicity, dark skin, different dietary patterns and other
racial differences.
The overall response to oral TKI therapy was 30%. Patients
with an activating mutation of EGFR had a response rate of 74%,
while the response rate in patients with wild type EGFR was 5%,
which was a statistically significant difference, p,0.001. This is
very similar to what has been reported in the literature, with a
response rate of 72% in mutant positive patients, and a response
rate of 1.1% in mutant negative patients [5]. The slightly higher
response rate in our mutant negative patients probably indicates
that we were not able to detect the EGFR mutation, when it was in
fact present, or that there were other genetic events in the EGFR or
alternative pathway that conferred sensitivity to oral TKI, in spite
of lack of EFGR mutation. Other studies report varying response
rates to oral TKI in EGFR negative patients. In a study by Han et
al, the response rate to Gefitinib was 25.9% in EGFR mutation
negative patients, compared to 84.6% in EGFR mutant patients
[14]. Yang et al reported a 20% response rate to Gefitinib in
EGFR negative patients while Han et al reported a response rate of
13.7% [14,15]. The reason for the wide range of response rates to
oral TKI therapy in patients, who are not detected to carry an
EGFR activating mutation, is due to the varying sensitivities of the
method used to detect the EGFR mutation. In our study, 4 patients
who were detected to harbor activating mutations in the EGFR
tyrosine kinase domain were found to be resistant to Gefitinib at
their 2 to 3-month follow-up scan. This might be possibly due to
the development of secondary mutations resulting in an acquired
resistance to EGFR targeted therapies. Thus it is necessary to look
at more markers for the effective prediction of the response to
EGFR-TKIs and it is also necessary to obtain biopsies of the
primary tumor subsequently during the course of the treatment to
detect the presence of secondary mutations that could alter the
response of the patients to the drugs [6].
Figure 1. Survival by EGFR mutation status. (A) Progression-free survival (PFS) for the EGFR mutant patients was 10 months (95% CI: 8–11.9
months), while the estimated median PFS for EGFR mutation negative patients was 2 months (95% CI: 1.5–2.5 months), p = 0.000 by log rank test
(Mantel Cox). (B) Overall survival (OS) for EGFR mutant patients was 21 months (95% CI: 12.4–25.6 months), while the estimated median OS for EGFR
mutantion negative patients was 10 months (95% CI: 7.4–12.6 months), p = 0.001 by log rank test (Mantel Cox).
doi:10.1371/journal.pone.0061561.g001
Table 3. Toxicities.
None Grade 1 Grade 2 Grade 3
Skin toxicity 77 10 10 14
GI toxicity 103 5 2 1
doi:10.1371/journal.pone.0061561.t003
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In terms of survival, the estimated progression free survival
(PFS) for all the patients was 4 months. The PFS for patients with
EGFR mutation was significantly longer at 10 months, as
compared to an estimated PFS of 2 months for EGFR negative
patients, p = 0.000 by log rank test. The estimated overall survival
for all patients was 13 months. The estimated median OS of the
patients with EGFR activating mutations was significantly longer at
21 months, as compared to an estimated median OS of 10 months
for EGFR negative patients, p = 0.001 by log rank test. In the
updated survival results of the IPASS study, the median PFS in
mutation positive patients was 9.5 months versus 1.5 months for
mutation negative patients, while the OS in mutation positive
patients was 21.6 months versus 11.2 months in EGFR-negative
patients. In their study on patients with EGFR activating
mutations, Maemondo et al reported a PFS of 10.8 months and
an OS of 30.5 months following gefitinib therapy [16]. Thus, the
survival results in our patients are similar to the results previously
reported in the literature.
Thus, Indian patients with EGFR activating mutations have a
significantly better response rate, progression free survival and
overall survival when treated with EGFR targeted therapies.
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